Literature DB >> 17507473

Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions.

Joshua C Grieger1, Jarrod S Johnson, Brittney Gurda-Whitaker, Mavis Agbandje-McKenna, R Jude Samulski.   

Abstract

Over the past 2 decades, significant effort has been dedicated to the development of adeno-associated virus (AAV) as a vector for human gene therapy. However, understanding of the virus with respect to the functional domains of the capsid remains incomplete. In this study, the goal was to further examine the role of the unique Vp1 N terminus, the N terminus plus the recently identified nuclear localization signal (NLS) (J. C. Grieger, S. Snowdy, and R. J. Samulski, J. Virol 80:5199-5210, 2006), and the virion pore at the fivefold axis in infection. We generated two Vp1 fusion proteins (Vp1 and Vp1NLS) linked to the 8-kDa chemokine domain of rat fractalkine (FKN) for the purpose of surface exposure upon assembly of the virion, as previously described (K. H. Warrington, Jr., O. S. Gorbatyuk, J. K. Harrison, S. R. Opie, S. Zolotukhin, and N. Muzyczka, J. Virol 78:6595-6609, 2004). The unique Vp1 N termini were found to be exposed on the surfaces of these capsids and maintained their phospholipase A2 (PLA2) activity, as determined by native dot blot Western and PLA2 assays, respectively. Incorporation of the fusions into AAV type 2 capsids lacking a wild-type Vp1, i.e., Vp2/Vp3 and Vp3 capsid only, increased infectivity by 3- to 5-fold (Vp1FKN) and 10- to 100-fold (Vp1NLSFKN), respectively. However, the surface-exposed fusions did not restore infectivity to AAV virions containing mutations at a conserved leucine (Leu336Ala, Leu336Cys, or Leu336Trp) located at the base of the fivefold pore. EM analyses suggest that Leu336 may play a role in global structural changes to the virion directly impacting downstream conformational changes essential for infectivity and not only have local effects within the pore, as previously suggested.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507473      PMCID: PMC1951316          DOI: 10.1128/JVI.00580-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini.

Authors:  Stephanie Kronenberg; Bettina Böttcher; Claus W von der Lieth; Svenja Bleker; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly.

Authors:  S F Cotmore; A M D'abramo; C M Ticknor; P Tattersall
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

4.  Canine parvovirus capsid structure, analyzed at 2.9 A resolution.

Authors:  Q Xie; M S Chapman
Journal:  J Mol Biol       Date:  1996-12-06       Impact factor: 5.469

5.  Nucleotide sequence and organization of the adeno-associated virus 2 genome.

Authors:  A Srivastava; E W Lusby; K I Berns
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

6.  Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry.

Authors:  Glen A Farr; Li-guo Zhang; Peter Tattersall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-11       Impact factor: 11.205

7.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection.

Authors:  C Summerford; J S Bartlett; R J Samulski
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

9.  Cell lines for the production of recombinant adeno-associated virus.

Authors:  K R Clark; F Voulgaropoulou; D M Fraley; P R Johnson
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

10.  Functional implications of the structure of the murine parvovirus, minute virus of mice.

Authors:  M Agbandje-McKenna; A L Llamas-Saiz; F Wang; P Tattersall; M G Rossmann
Journal:  Structure       Date:  1998-11-15       Impact factor: 5.006

View more
  30 in total

1.  Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.

Authors:  Brittney L Gurda; Christina Raupp; Ruth Popa-Wagner; Matthias Naumer; Norman H Olson; Robert Ng; Robert McKenna; Timothy S Baker; Jürgen A Kleinschmidt; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 2.  Recombinant adeno-associated virus transduction and integration.

Authors:  Brian R Schultz; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

3.  Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking.

Authors:  Hyun-Joo Nam; Brittney L Gurda; Robert McKenna; Mark Potter; Barry Byrne; Maxim Salganik; Nicholas Muzyczka; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2011-09-07       Impact factor: 5.103

4.  Unique characteristics of AAV1, 2, and 5 viral entry, intracellular trafficking, and nuclear import define transduction efficiency in HeLa cells.

Authors:  Nicholas W Keiser; Ziying Yan; Yulong Zhang; Diana C M Lei-Butters; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2011-06-28       Impact factor: 5.695

Review 5.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

6.  Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2.

Authors:  Antonette Bennett; Annahita Keravala; Victoria Makal; Justin Kurian; Brahim Belbellaa; Rangoli Aeran; Yu-Shan Tseng; Duncan Sousa; John Spear; Mehdi Gasmi; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2019-12-16       Impact factor: 2.867

7.  Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus.

Authors:  Sarah C Nicolson; R Jude Samulski
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

8.  Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.

Authors:  Chengwen Li; Yi He; Sarah Nicolson; Matt Hirsch; Marc S Weinberg; Ping Zhang; Tal Kafri; R Jude Samulski
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

9.  Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking.

Authors:  Balasubramanian Venkatakrishnan; Joseph Yarbrough; John Domsic; Antonette Bennett; Brian Bothner; Olga G Kozyreva; R Jude Samulski; Nicholas Muzyczka; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

10.  Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging.

Authors:  Lauren M Drouin; Bridget Lins; Maria Janssen; Antonette Bennett; Paul Chipman; Robert McKenna; Weijun Chen; Nicholas Muzyczka; Giovanni Cardone; Timothy S Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.